Loading...

NECLIFE Nectar Lifescience Ltd Quarterly Earnings Reports Announcement

Nctr

NCLF

Nectar Lifescience Ltd

(NECLIFE)

2025 Announcement

Litigation updation

Regulatory Compliance

Shareholder Outreach

Regulatory Compliance

Trading Window Closure

Litigation Update

Inter-corporate loan

Civil Litigation

Wholly Owned Subsidiary

Debt Investment

Asset Acquisition

SAST Regulation 10(7) discl...

Postal Ballot Publication

Regulatory disclosure (SEBI...

Regulation 10(6) disclosure

Reg 10(6 disclosure)

Newspaper publication of re...

MOA amendment and expansion

Unaudited financial results

Equity Buyback Extinguishment

Tender Offer Buyback

Buyback Completed

Regulatory Compliance

Buyback Advertisement

Buyback details

Trading Window Closure

Shareholding disclosure

Public Announcement Corrige...

Buyback of Shares

Buyback and Appointment

Tender offer route

SEBI PIT Disclosures

Trading Window Closure

Board meeting for buyback

Newspaper Publication

Office relocation

Quarterly earnings release

Slump Sale Completion

Management Change

Board Meeting Notice

Management Change

Regulatory Disclosure

SBICAP Disclosure

Insider Trading Disclosure

Director Withdrawal

Debt Repayment Completed

Slump Sale Update

Compliance Certificate

Asset Sale Update

Slump Sale Update

Regulatory Disclosure

Annual Report Link

AGM Notice Published

Litigation Update

30th AGM Notice

Saksham Niveshak Campaign

Financial Results Update

Financial Results Update

Manufacturing Certification

EGM Corrigendum

Board Fines Update

Newspaper Publication

EGM Notice Published

Financial Results Publication

Regulatory Fine Update

Strategic Business Sale

Compliance Certificate

Litigation Update

Management Change

Show Cause Notice

Supreme Court Order

Director Change

GST Appeal Update

Litigation Update

Compliance Report

Court Ruling Update

Tax Demand Update

Certification Announcement

Ongoing Litigation

Compliance Certificate

Litigation Update

Management Change

Investor Meeting

EU Regulatory Update

EU Inspection Update

Resignation Announcement

Financial Results Publication

Investor Presentation

Q3 FY25 Performance

Litigation Update

Tax Relief Update

Investor Meetings

Compliance Certificate

Insider Trading Disclosure

Investment Agreement Termin...

Litigation Update

Litigation Update

Financial Results Released

Management Change

Investor Presentation

Legal Action Update

Court Ruling Update

Business Presentation

Litigation Update

Tax Dispute Update

Litigation Update

Litigation Disclosure

Regulatory Compliance

Director Cessation

Volume Increase Clarification

AGM Notice Published

Litigation Update

Financial Results Published

Publication of Notice

Certificate Submission

Secretarial Compliance Report

Financial Results Publication

Litigation Disclosure

Certificate Submission

Compliance Submission

Compliance Certification

Company Clarification

Publication of Financial Re...

Change in Management

Update on Litigation Case

Financial Results Publication

Financial Statements

Civil Litigations, Insuranc...

Newspaper Publication

Asset Sale, Rights Offerings

Publication of Financial Re...

Management Changes

External Links:

Data:

Nectar Lifesciences Ltd. reports Q3 FY25 revenue of ₹4,543.34 million, showing growth compared to previous quarters, with projected FY26 revenue growth of 7-10%. The company anticipates EBITDA margins to expand 100-150 bps annually, along with debt reduction efforts to enhance profitability.

AI Assistant

Nectar Lifescience Ltd

2025

Announcement

Find Answers

Ask about any part of the document to get insights, explanations, or key details.